Quel est le prix pour Freeline Therapeutics Holdings plc (FRLN)

Le prix pour Freeline Therapeutics Holdings plc (FRLN) est $6.48

Quelle est la capitalisation boursière pour Freeline Therapeutics Holdings plc (FRLN)

La capitalisation boursière pour Freeline Therapeutics Holdings plc (FRLN) est $15.41M

Freeline Therapeutics Holdings plc (FRLN) Prix et Capitalisation Boursière

Freeline Therapeutics Holdings plc is a biopharmaceutical company, currently in its clinical development phase, focused on creating groundbreaking gene therapies. These innovative treatments leverage adeno-associated virus (AAV) vector technology to tackle inherited, systemic, and severely debilitating genetic conditions. The company's leading therapeutic candidate, verbrinacogene setparvovec (FLT180a), is presently undergoing Phase 1/2 clinical trials for the management of hemophilia B in adult males. Furthermore, Freeline's pipeline features FLT190, which is also in Phase 1/2 clinical evaluation for treating Fabry disease, and FLT201, a gene therapy designed to target the liver for type 1 Gaucher disease, likewise progressing through Phase 1/2 trials. Beyond these specific programs, the company is actively pursuing research initiatives across a range of other systemic gene therapy indications. Freeline was established in 2015 and operates from its headquarters in Stevenage, United Kingdom.

Prix pour FRLN	L’actif B	La capitalisation boursière de B	Résultats
$2,230,817 $15.41M	NVDA	$5.307T	+34,426,091.87%
$1,913,068 $15.41M	AAPL	$4.551T	+29,522,559.17%
$1,746,440 $15.41M	GOOG	$4.154T	+26,951,137.90%
$1,508,578 $15.41M	MSFT	$3.589T	+23,280,428.23%
$1,175,758 $15.41M	AMZN	$2.797T	+18,144,312.93%

Prix pour FRLN

L’actif B

La capitalisation boursière de B

Résultats

$2,230,817 $15.41M